Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Curr Opin Urol. 2018 Jul;28(4):375-382. doi: 10.1097/MOU.0000000000000506.
With this review, we describe the most recent advances in active surveillance as well as diagnosis and management of small renal masses (SRMs).
We discuss diagnosis, differentiation of solid from cystic lesions, risk prediction and treatment of the SRM. A better understanding of the disease facilitates the use of more conservatory treatments, such as active surveillance. Active surveillance has been increasingly accepted not only for SRM, but also for larger tumors and even metastatic patients. Exiting advances in risk prediction will help us define which patients can be safely managed with active surveillance and which require immediate treatment. Meanwhile, the use of renal tumor biopsies is still an important tool for these cases.
Active surveillance is an option for many patients with renal masses. Noninvasive methods for diagnosis and risk prediction are being developed, but meanwhile, renal tumor biopsy is a useful tool. A better understanding of the disease increases the number of patients who can undergo active surveillance fully certain of the safety of their management.
本文描述了小肾肿瘤(SRM)主动监测以及诊断和治疗的最新进展。
我们讨论了 SRM 的诊断、实性与囊性病变的鉴别、风险预测和治疗。对疾病的更好理解促进了更保守治疗的应用,如主动监测。主动监测不仅越来越多地用于 SRM,也用于更大的肿瘤,甚至转移性患者。现有的风险预测进展将帮助我们确定哪些患者可以安全地接受主动监测,哪些患者需要立即治疗。同时,肾肿瘤活检仍然是这些病例的重要工具。
主动监测是许多肾肿瘤患者的一种选择。目前正在开发用于诊断和风险预测的非侵入性方法,但与此同时,肾肿瘤活检是一种有用的工具。对疾病的更好理解增加了可以进行主动监测的患者数量,使他们对管理的安全性有充分的把握。